Results 171 to 180 of about 586,786 (282)

Club Cells in Nasal Epithelial Repair: Insights From an IL‐13‐Induced Inflammatory Model

open access: yesAllergy, EarlyView.
Four inflammatory endotypes of CRSwNP, defined by eosinophil and neutrophil infiltration, show distinct patterns of basal, club, ciliated, and goblet cell expression in nasal epithelium. Using an ALI‐HNECs model, we demonstrate that IL‐13 impairs mucociliary function by promoting club‐to‐goblet cell differentiation while inhibiting club‐to‐ciliated ...
Zhi‐Qun Huang   +13 more
wiley   +1 more source

“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps

open access: yesAllergy, EarlyView.
This study aimed to evaluate the feasibility of extending dupilumab dosing intervals in T2‐CRSwNP by assessing how many patients maintain disease control with once‐every‐12‐weeks (Q12W) dosing and comparing clinical characteristics of super‐responders and excellent responders. Tapering of dupilumab to Q12W appears feasible in super‐responding patients.
P. E. Vonk   +13 more
wiley   +1 more source

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

open access: yesAllergy, EarlyView.
ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier   +221 more
wiley   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

open access: yesAllergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh   +7 more
wiley   +1 more source

Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An EAACI Task Force Report

open access: yesAllergy, EarlyView.
ABSTRACT Chronic rhinosinusitis (CRS) and asthma are prevalent conditions that often coexist. These diseases share common inflammatory mechanisms, such as T‐helper cell 2 (T2)‐high inflammation, driven by interleukin (IL)‐4, IL‐5, and IL‐13 cytokines.
Sanna Toppila‐Salmi   +21 more
wiley   +1 more source

Real‐World Performance of FIT Triage for Symptomatic Colonoscopy: Analysis of the UK National Endoscopy Database (NED)

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
National endoscopy data show that FIT‐based triage clearly outperforms symptom‐based referral for colorectal cancer risk stratification. FIT ≥ 10 identifies high‐risk symptomatic patients, while FIT < 10 confers very low cancer risk, supporting FIT as the primary tool for prioritising colonoscopy in symptomatic pathways.
David Beaton   +4 more
wiley   +1 more source

Predicting ADR from PDR and individual adenoma-to-polyp-detection-rate ratio for screening and surveillance colonoscopies: A new approach to quality assessment

open access: yesUnited European Gastroenterology journal, 2017
Christoph Schramm   +8 more
semanticscholar   +1 more source

Anti‐inflammatory effects of physical stimuli: The central role of networks in shaping the future of pharmacological research

open access: yesBritish Journal of Pharmacology, EarlyView.
Addressing complexity in the study of life sciences through Systems Biology and Systems Medicine has been transformative, making Systems Pharmacology the next logical step. In this review, we focus on physical stimuli, whose potential in pharmacology has been neglected, despite demonstrated therapeutic properties.
Veronica Paparozzi   +10 more
wiley   +1 more source

Early and Sustained Asthma Control and Remission in Real‐World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC‐2

open access: yesClinical &Experimental Allergy, EarlyView.
Real‐world patients with severe eosinophilic asthma treated with benralizumab showed early and sustained improvements in symptoms. Clinically meaningful improvements began as early as one week after benralizumab initiation, regardless of previous biologic use, and further improved over the following year.
Erika Penz   +12 more
wiley   +1 more source

Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N‐ERD Patients

open access: yesClinical &Experimental Allergy, EarlyView.
Dupilumab therapy reduced elevated type 2 cytokine responses post‐ASA provocation in N‐ERD patients, independent of ASA tolerance, and revealed novel mechanistic insights by modulating acute type 2 immunity. Transcriptomic analysis showed concurrent downregulation of lipid and peroxisome pathways during ASA challenge in N‐ERD patients after 24 weeks of
Julia Eckl‐Dorna   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy